Opus Genetics vs Keros Therapeutics
IRD and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and KROS compare
Opus Genetics is the larger company, worth 1.6 times as much as Keros Therapeutics ($331M against $204M).
Opus Genetics grew revenue faster over the last twelve months (−45.9% versus −83.4% for Keros Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −1727% at Opus Genetics.
Keros Therapeutics scores higher on the StockData Score (9 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $331M | $204M |
| Share price | $3.98 | $10.30 |
| Change, 1 year | 107% | −41.0% |
| Change, 5 years | 9.3% | −82.8% |
| Beta (5Y) | 0.97 | 1.11 |
| Employees | 27 | 78 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 41.8× | 5.1× (better) |
| P/B | 8.6× | 0.7× (better) |
| FCF yield | – | −23.6% |
| Fair value | $0.711 | $24.09 |
| Margin of safety | −460% | 57.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.9% (better) | −83.4% |
| Net income growth (TTM) | – | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Operating margin | −778% | −181% (better) |
| Net margin | −1727% | −153% (better) |
| FCF margin | – | −119% |
| Return on equity | −616% | −12.6% (better) |
| Return on invested capital | – | −389% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −217.5× | – |
| Current ratio | 9.65 | 18.14 (better) |
| Altman Z-score | −2.02 | 2.37 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.73% | – |
| Shareholder yield | −0.73% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 101% |
| Held by insiders | 37.6% | 53.3% |
| Insider net buying, 12 months | −$19.4M | −$447K (better) |
| Short interest, % of float | 20.9% | 11.7% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.